IQVIA (IQV) Competitors

IQVIA logo
$265.14 +0.02 (+0.01%)
Closing price 03:59 PM Eastern
Extended Trading
$264.80 -0.34 (-0.13%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQV vs. ICLR, MEDP, TECH, A, and CRL

Should you buy IQVIA stock or one of its competitors? IQVIA's main competitors and comparable companies include Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IQVIA compare to Icon?

Icon (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Icon$8.23B1.81$229.34M$5.8133.50
IQVIA$17.31B2.53$1.36B$8.2332.25

Icon has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

95.6% of Icon shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IQVIA has a net margin of 8.05% compared to Icon's net margin of 5.45%. IQVIA's return on equity of 30.02% beat Icon's return on equity.

Company Net Margins Return on Equity Return on Assets
Icon5.45% 7.73% 4.39%
IQVIA 8.05%30.02%6.52%

Icon currently has a consensus price target of $213.76, indicating a potential upside of 9.82%. IQVIA has a consensus price target of $294.21, indicating a potential upside of 10.84%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Icon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icon
1 Sell rating(s)
9 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.50
IQVIA
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90

In the previous week, IQVIA had 4 more articles in the media than Icon. MarketBeat recorded 7 mentions for IQVIA and 3 mentions for Icon. IQVIA's average media sentiment score of 0.82 beat Icon's score of 0.65 indicating that IQVIA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Icon
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IQVIA
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

IQVIA beats Icon on 13 of the 17 factors compared between the two stocks.

How does IQVIA compare to Medpace?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

89.6% of IQVIA shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$17.31B2.53$1.36B$8.2332.25
Medpace$2.53B7.23$451.12M$18.0436.25

IQVIA has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Medpace has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Medpace has a net margin of 18.24% compared to IQVIA's net margin of 8.05%. Medpace's return on equity of 99.76% beat IQVIA's return on equity.

Company Net Margins Return on Equity Return on Assets
IQVIA8.05% 30.02% 6.52%
Medpace 18.24%99.76%24.47%

In the previous week, IQVIA had 2 more articles in the media than Medpace. MarketBeat recorded 7 mentions for IQVIA and 5 mentions for Medpace. Medpace's average media sentiment score of 1.53 beat IQVIA's score of 0.82 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IQVIA
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

IQVIA currently has a consensus target price of $294.21, indicating a potential upside of 10.84%. Medpace has a consensus target price of $649.27, indicating a potential downside of 0.71%. Given IQVIA's stronger consensus rating and higher probable upside, research analysts clearly believe IQVIA is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23

Summary

IQVIA beats Medpace on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Bio-Techne currently has a consensus price target of $68.92, suggesting a potential downside of 5.33%. IQVIA has a consensus price target of $294.21, suggesting a potential upside of 10.84%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Bio-Techne.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne
1 Sell rating(s)
14 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.12
IQVIA
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90

Bio-Techne has a net margin of 13.95% compared to IQVIA's net margin of 8.05%. IQVIA's return on equity of 30.02% beat Bio-Techne's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Techne13.95% 13.00% 10.57%
IQVIA 8.05%30.02%6.52%

In the previous week, Bio-Techne and Bio-Techne both had 7 articles in the media. Bio-Techne's average media sentiment score of 1.14 beat IQVIA's score of 0.82 indicating that Bio-Techne is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Techne
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IQVIA
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$1.22B9.41$181.86M$1.0966.79
IQVIA$17.31B2.53$1.36B$8.2332.25

Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Summary

IQVIA beats Bio-Techne on 9 of the 16 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

IQVIA (NYSE:IQV) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Agilent Technologies had 3 more articles in the media than IQVIA. MarketBeat recorded 10 mentions for Agilent Technologies and 7 mentions for IQVIA. IQVIA's average media sentiment score of 0.82 beat Agilent Technologies' score of 0.46 indicating that IQVIA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IQVIA
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agilent Technologies
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

89.6% of IQVIA shares are held by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 0.2% of Agilent Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Agilent Technologies. IQVIA is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$17.31B2.53$1.36B$8.2332.25
Agilent Technologies$7.37B6.65$1.30B$5.0834.25

IQVIA currently has a consensus target price of $294.21, indicating a potential upside of 10.84%. Agilent Technologies has a consensus target price of $181.45, indicating a potential upside of 4.29%. Given IQVIA's stronger consensus rating and higher possible upside, equities analysts clearly believe IQVIA is more favorable than Agilent Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90
Agilent Technologies
0 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.82

IQVIA has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to IQVIA's net margin of 8.05%. IQVIA's return on equity of 30.02% beat Agilent Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
IQVIA8.05% 30.02% 6.52%
Agilent Technologies 19.53%24.45%13.09%

Summary

IQVIA beats Agilent Technologies on 10 of the 17 factors compared between the two stocks.

How does IQVIA compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Charles River Laboratories International currently has a consensus target price of $311.67, suggesting a potential downside of 7.86%. IQVIA has a consensus target price of $294.21, suggesting a potential upside of 10.84%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International
1 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.71
IQVIA
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90

Charles River Laboratories International has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

IQVIA has higher revenue and earnings than Charles River Laboratories International. IQVIA is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$3.98B4.08-$144.34M$0.91371.73
IQVIA$17.31B2.53$1.36B$8.2332.25

IQVIA has a net margin of 8.05% compared to Charles River Laboratories International's net margin of 1.01%. IQVIA's return on equity of 30.02% beat Charles River Laboratories International's return on equity.

Company Net Margins Return on Equity Return on Assets
Charles River Laboratories International1.01% 16.95% 6.93%
IQVIA 8.05%30.02%6.52%

In the previous week, Charles River Laboratories International had 2 more articles in the media than IQVIA. MarketBeat recorded 9 mentions for Charles River Laboratories International and 7 mentions for IQVIA. Charles River Laboratories International's average media sentiment score of 0.93 beat IQVIA's score of 0.82 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Charles River Laboratories International
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IQVIA
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

IQVIA beats Charles River Laboratories International on 10 of the 17 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IQV vs. The Competition

MetricIQVIALife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$43.70B$10.83B$7.83B$23.18B
Dividend YieldN/A1.45%2.47%3.78%
P/E Ratio32.2251.4934.3229.41
Price / Sales2.527.118.003.24
Price / Cash14.8426.7921.0215.64
Price / Book6.815.804.764.04
Net Income$1.36B$57.47B$3.52B$1.08B
7 Day Performance-4.91%-5.43%-5.35%-3.09%
1 Month Performance-0.69%-0.97%-3.62%-1.21%
1 Year Performance19.94%18.51%-0.62%5.64%

IQVIA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IQV
IQVIA
3.8324 of 5 stars
$265.14
+0.0%
$294.21
+11.0%
+20.1%$43.70B$17.31B32.2293,000
ICLR
Icon
3.8166 of 5 stars
$207.59
+1.4%
$213.76
+3.0%
+20.0%$15.55B$8.25B35.7340,100
MEDP
Medpace
2.6697 of 5 stars
$672.93
+3.0%
$649.27
-3.5%
+10.8%$18.37B$2.53B36.416,200
TECH
Bio-Techne
2.1735 of 5 stars
$72.83
+0.1%
$68.92
-5.4%
+22.6%$11.42B$1.22B42.283,000
A
Agilent Technologies
3.7705 of 5 stars
$180.09
+3.0%
$181.45
+0.8%
+18.4%$49.95B$6.95B29.2418,100

Related Companies and Tools


This page (NYSE:IQV) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners